biolitec AG: biolitec AG back in the profit zone - EBIT rises to Euro 1.46 million in the second quarter 2009/2010 - cost savings take effect

biolitec AG / Half Year Results/Half Year Results

26.02.2010 16:38

Dissemination of an Ad hoc announcement according to § 15 WpHG,
transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

 

biolitec AG back in the profit zone - EBIT rises to Euro 1.46 million in
the second quarter 2009/2010 - cost savings take effect

Jena, February 26th, 2010 - biolitec AG, Jena, listed in the Prime Standard
of the Frankfurt stock exchange (ISIN DE0005213409), realized a
consolidated revenue of Euro 14.4 million in the first two quarters of the
fiscal year 2009/2010 and an EBIT amounting  to Euro 1.46 million. With
this, biolitec has already exceeded the previous year's result in the
reference period by over Euro 2 million.

While turnover in the second quarter exceeded the first by a healthy 33%,
the 6 months turnover was still below last year's by 6.4%. The cost savings
in the first two quarters of the fiscal year 2009/2010 had a considerable
impact on the company's profitability.

The gross profit slightly exceeded Euro 10 million (last fiscal year: Euro
10.1 million) and EBIT amounted to Euro 1.46 million (previous year: Euro -
0.59 million). R&D expenditures for the first six months of the fiscal year
2009/2010 of Euro 1.47 million (about 10% of sales) compared to the
previous year (Euro 2.60 million) remained reduced, but on the required
level to ensure growth in the long-term and permanent profitability. Sales
and marketing expenses were reduced remarkably to Euro 4.52 million
compared to Euro 6.25 million in last year's period.

The revenue posted by the laser segment of Euro 3.57 million was lower than
in the prior year (Euro 4.64 million) due to the investment restraint in
hospitals and private clinics. The fiber optics and laser probes segment
contributed Euro 10.26 million to the group's total revenue and exceeded
the previous year's level, indicating a persistent market and further
increasing number of treatments. Main contributions to sales were BPH laser
treatments (LIFE(TM)) and endoluminal laser procedures for veins (ELVeS(TM)
PainLess).

biolitec AG's major revenues were again generated in Europe and North
America. Sales in North America with Euro 5.74 million were above previous
year's level. European sales amounted to Euro 6.86 million. Asia and ROW
sales of Euro 1.86 million (Last year Euro 1.92 million) decreased
slightly. biolitec AG expects sales growth to pick up during the fiscal
year, when the propensity to invest  rises again. Due to the improved cost
structure compared to the previous year the profit should increase further.

The two mainstays of sales LIFE(TM) for the treatment of BPH and ELVeS(TM)
PainLess for the treatment of varicose veins present considerable growth
potential for the future. With Evolve(R) DUAL - a laser with parallel
working wavelengths - the TWISTER(TM) fiber in the field of urology as well
as the new RADIAL fiber for the treatment of varicose veins with 360 
circumferential energy emission ,innovative fiberoptic technology, was
introduced to this promising markets. With these two already established
systems biolitec expects substantial revenue potential for the upcoming
financial years.

Due to the staff reduction and the cost savings in total, we expect further
stabilization of profits. Inventories and working capital will further
decrease in the coming quarters.


26.02.2010 Ad hoc announcement, Financial News and Media Release
distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      biolitec AG
              Winzerlaer Straße 2a
              07745 Jena
              Deutschland
Phone:        +49 (0) 3641 508 550
Fax:          +49 (0) 3641 508 599
E-mail:       info@biolitec.de
Internet:     www.biolitec.de
ISIN:         DE0005213409
WKN:          521340
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, München, Düsseldorf, Stuttgart, Hamburg
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------